Purpose
To support the early-stage development and validation of Gennova’s thermostable self-amplifying RNA (saRNA) vaccine platform with a specific focus on achieving durable immune responses suitable for low- and middle-income countries (LMICs).
Grantee
Division
Global Health
Date
SEPTEMBER 2025
Region served
GLOBAL
Committed amount
$2,319,620
Grant topic
Vaccine Development
Duration (months)
31
Grantee location
Pune, Maharashtra, India
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.